FDA Places Clinical Holds on Regenxbio's RGX-111 and RGX-121 Gene Therapy Trials After Brain Tumor in Patient
FDA Places Clinical Holds on Regenxbio's RGX-111 and RGX-121 Gene Therapy Trials After Brain Tumor in Patient
Posts
Zhongmou Therapeutics Reports First-in-Human Success of Optogenetic Gene Therapy ZM-02 for Retinitis Pigmentosa
Zhongmou Therapeutics Reports First-in-Human Success of Optogenetic Gene Therapy ZM-02 for Retinitis Pigmentosa
- Get link
- X
- Other Apps